Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Cagrilintide
Max Weight Loss0%
Studies8
Participants1,847
StatusLimited

Cagrilintide

Long-Acting Amylin Receptor Agonist

Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.

Clinical Safety Profile

Reported Side Effects

Nausea (most common, transient)
Vomiting and gastrointestinal upset
Decreased appetite (therapeutic effect)
Injection site reactions
Fatigue and headache
Diarrhea or constipation
Abdominal pain
Dizziness

Side Effect Management (Clinical Trial Data)

Nausea
Common
18.2%
Vomiting
Infrequent
8.7%
Diarrhea
Occasional
12.1%
Constipation
Infrequent
6.4%
Abdominal Pain
Infrequent
9.8%
Injection Site Reaction
Infrequent
4.2%
Fatigue
Infrequent
7.3%
Headache
Infrequent
5.9%

Side Effect Management Strategies

Nausea: Take with food, smaller meals, ginger supplements
Vomiting: Slower dose escalation, anti-emetics if severe
Diarrhea: Adequate hydration, probiotics, bland diet
Constipation: Increase fiber intake, adequate fluids, light exercise

Clinical Safety Metrics

Good
Overall Safety Rating
12.7%
Discontinuation Rate
Phase 3
Approved Status

CONTRAINDICATIONS

• Severe gastroparesis or gastric emptying disorders
• Known hypersensitivity to cagrilintide
• Active inflammatory bowel disease
• History of severe pancreatitis

Medical Disclaimer

This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.